{
  "pathway_name": "colon-cancer-clinical-pathways-v1-2025-508h",
  "original_file": "colon-cancer-clinical-pathways-v1-2025-508h_extracted.json",
  "processed_at": "2025-03-29T01:01:09.142041",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY: COLON CANCER (V1-2025)\n\n## OVERVIEW\n\nThis comprehensive clinical pathway provides evidence-based guidelines for the management of colon cancer across all stages, with emphasis on personalized treatment approaches based on molecular characteristics, disease stage, and patient-specific factors. The pathway is designed to guide clinicians through diagnosis, staging, treatment selection, and surveillance.\n\n## INITIAL ASSESSMENT AND STAGING\n\n### Presumptive Service Connection for Veterans\nColon cancer is considered presumptively service-connected for:\n- **Atomic Veterans**: Exposure to ionizing radiation during military service\n- **Gulf War and Post-9/11 Veterans**: Service on/after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen; or service on/after August 2, 1990 in Southwest Asia theater of operations or Somalia\n\n## MOLECULAR TESTING\n\n### Testing Indications\n- **Stage I-III**: MMR/MSI testing\n- **Stage IV**: Comprehensive genomic profiling\n- **Age <50**: Germline testing\n- **Age \u226550 with concerning history**: Consider genetic evaluation\n\n### Testing Algorithm\n1. **Somatic Testing**:\n   - **Stages I-III**: MMR by IHC and/or MSI by PCR\n   - **Stage IV**: CGP including MMR/MSI, RAS, BRAF, HER2, NTRK, KRAS G12C\n\n2. **If dMMR/MSI-H detected**:\n   - For MLH1/PMS2 loss: BRAF V600E testing\n     - If BRAF mutated: Suggests sporadic\n     - If BRAF unmutated: MLH1 promoter methylation testing\n       - If methylated: Likely sporadic\n       - If unmethylated: Germline Lynch testing\n\n3. **Germline Testing**:\n   - **Minimum gene panel**: APC, AXIN2, BMPR1A, CHEK2, EPCAM, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, SMAD4, STK11, TP53\n\n## STAGE-SPECIFIC TREATMENT ALGORITHMS\n\n### STAGE I COLON CANCER\n\n#### For Completely Resected Malignant Polyp\n1. **Assess for high-risk features**:\n   - **Sessile Polyps**: Poor differentiation, LVI, submucosal invasion >1mm, positive cautery margin, tumor budding\n   - **Pedunculated Polyps**: Poor differentiation, LVI, tumor <1mm from margin\n\n2. **Management**:\n   - **High-risk features present**: Surgical resection \u2192 follow appropriately staged pathway\n   - **No high-risk features**:\n     - **Sessile polyp**: Shared decision-making (surgical resection vs. surveillance)\n     - **Pedunculated polyp**: Endoscopic surveillance\n\n#### For Surgically Resected Cancer\n- Active surveillance (no adjuvant therapy required)\n\n### STAGE II COLON CANCER\n\n#### Initial Requirements\n- DPYD testing before fluoropyrimidine therapy\n- MMR/MSI status determination\n\n#### Risk Stratification Criteria\n- Clinical obstruction\n- Localized tumor perforation\n- Poorly differentiated histology (pMMR only)\n- Lymphovascular/perineural invasion\n- <12 harvested lymph nodes\n- Positive/close margins (\u22641mm)\n- High tumor budding\n\n#### For dMMR (MSI-H) Patients\n- **High Risk** (\u22651 factor): Shared decision-making between:\n  - CAPOX (3 months) or mFOLFOX6 (3-6 months)\n  - Observation\n- **Low Risk** (no factors): Observation\n\n#### For pMMR (MSS) Patients\n- **T4 tumors**: Shared decision-making between:\n  - CAPOX (3 months) or mFOLFOX6 (3-6 months)\n  - Capecitabine or fluorouracil (6 months)\n- **T3 tumors with \u22652 risk factors**: Shared decision-making between:\n  - Capecitabine or fluorouracil (6 months)\n  - Observation\n- **No risk factors**: Observation\n\n### STAGE III COLON CANCER\n\n#### Initial Requirements\n- DPYD testing\n- MMR/MSI status determination\n\n#### For dMMR (MSI-H) Patients\n- **High Risk** (T4 and/or N2): CAPOX (6 months) or mFOLFOX6 (6 months)\n- **Low Risk** (T1-3, N1): CAPOX (3 months)\n\n#### For pMMR (MSS) Patients\n- **High Risk** (T4 and/or N2):\n  - If prohibitive neuropathy: Capecitabine or fluorouracil (6 months)\n  - Otherwise: CAPOX (6 months) or mFOLFOX6 (6 months)\n- **Low Risk** (T1-3, N1): Shared decision-making between:\n  - CAPOX (3 months)\n  - Capecitabine or fluorouracil (6 months)\n\n### STAGE IV COLON CANCER\n\n#### Initial Evaluation\n- Comprehensive molecular testing (MMR/MSI, RAS, BRAF, HER2, NTRK, KRAS G12C)\n- Multidisciplinary discussion\n- Assessment of resectability and fitness for combination chemotherapy\n\n#### A. POTENTIALLY RESECTABLE DISEASE\n\n1. **Immediate Resection Candidates**:\n   - Metastasis and primary directed local therapy\n   - **Post-resection**:\n     - If oxaliplatin candidate: mFOLFOX6 or CAPOX (3 months)\n     - Otherwise: Capecitabine or fluorouracil (6 months)\n\n2. **Non-Immediate Resection Candidates**:\n   - **If oxaliplatin candidate**:\n     - For aggressive approach: mFOLFIRINOX \u00b1 bevacizumab (up to 4 months)\n     - Otherwise: mFOLFOX6 or CAPOX \u00b1 bevacizumab (up to 4 months)\n   - **If not oxaliplatin candidate**: FOLFIRI (up to 4 months)\n   - **Reassess resectability every 2 months**:\n     - If becomes resectable: Local therapy \u2192 Complete 6 months of chemotherapy\n     - If remains unresectable: Continue systemic therapy\n\n#### B. UNRESECTABLE DISEASE\n\n##### For dMMR (MSI-H) Patients\n- **First-line**: Pembrolizumab\n- **If progression**: Assess fitness for combination chemotherapy\n  - If fit: Follow pMMR first-line pathway\n  - If unfit: Follow unfit pathway\n\n##### For pMMR (MSS) Patients Fit for Combination Chemotherapy\n\n###### FIRST-LINE THERAPY\n- **RASwt, BRAFwt, left-sided primary**:\n  - If oxaliplatin candidate: mFOLFOX6/CAPOX + panitumumab\n  - Otherwise: FOLFIRI + panitumumab\n- **RASmut, BRAFwt, right-sided primary**:\n  - If bevacizumab candidate: mFOLFOX6/CAPOX + bevacizumab\n  - Otherwise: mFOLFOX6/CAPOX\n- **RASmut, BRAFwt (side not specified)**:\n  - If oxaliplatin candidate:\n    - If bevacizumab candidate: mFOLFOX6/CAPOX + bevacizumab\n    - Otherwise: mFOLFOX6/CAPOX\n  - If not oxaliplatin candidate:\n    - If bevacizumab candidate: FOLFIRI + bevacizumab\n    - Otherwise: FOLFIRI\n\n###### SECOND-LINE THERAPY\n- **Actionable mutations**:\n  - BRAF V600E positive: Encorafenib + panitumumab\n  - NTRK fusion positive: Larotrectinib\n  - HER2 overexpression/ERBB2 amplified + RASwt + BRAFwt: Trastuzumab + pertuzumab\n- **Without actionable mutations**:\n  - **Prior irinotecan-based regimen**:\n    - With prior anti-EGFR:\n      - If oxaliplatin candidate: mFOLFOX/CAPOX \u00b1 bevacizumab\n      - If not: Assess for KRAS G12C mutation\n        - If positive: Adagrasib + cetuximab\n        - If negative: Trifluridine tipiracil \u00b1 bevacizumab\n    - Without prior anti-EGFR: FOLFIRI/irinotecan + panitumumab\n  - **Prior oxaliplatin-based regimen**: FOLFIRI \u00b1 bevacizumab\n\n###### THIRD-LINE THERAPY\n- **HER2 overexpression**: Fam-trastuzumab deruxtecan\n- **RASwt, BRAFwt**:\n  - With prior anti-EGFR:\n    - If prior trifluridine tipiracil: Fruquintinib\n    - Otherwise: Panitumumab\n  - Without prior anti-EGFR:\n    - If bevacizumab candidate: Trifluridine tipiracil + bevacizumab\n    - Otherwise: Trifluridine tipiracil\n- **RASmut or BRAF mutant**:\n  - If KRAS G12C mutation: Adagrasib + cetuximab\n  - Otherwise:\n    - If prior trifluridine tipiracil: Fruquintinib\n    - If no prior trifluridine tipiracil:\n      - If bevacizumab candidate: Trifluridine tipiracil + bevacizumab\n      - Otherwise: Trifluridine tipiracil\n\n###### FOURTH-LINE THERAPY\n- **KRAS G12C mutation**: Adagrasib + cetuximab (if no prior KRAS G12C inhibitor)\n- **No KRAS G12C mutation**:\n  - Fruquintinib (if no prior failure)\n  - Trifluridine tipiracil + bevacizumab (if appropriate)\n  - mFOLFOX6/CAPOX (if well tolerated previously, >12 months since last use, no \u2265grade 2 neuropathy)\n  - FOLFIRI (if well tolerated previously, >12 months since last use)\n\n##### For pMMR (MSS) Patients Unfit for Combination Chemotherapy\n- **First-line**: Fluorouracil monotherapy (infusional preferred) or capecitabine\n- **Upon progression**:\n  - RASwt, BRAFwt:\n    - If HER2 overexpression: Trastuzumab + pertuzumab\n    - Otherwise: Panitumumab\n  - BRAF V600E mutation: Encorafenib + panitumumab\n  - RAS mutation or BRAF non-V600E: Irinotecan\n  - KRAS G12C mutation: Adagrasib + cetuximab\n\n## IMPORTANT CLINICAL CONSIDERATIONS\n\n### Timing of Therapy\n- Adjuvant chemotherapy should begin 6-8 weeks post-surgery\n- Delay beyond 3 months significantly reduces efficacy\n\n### DPYD Testing\n- Required before fluoropyrimidine therapy\n- If results show intermediate/poor metabolizer, consult pharmacist\n- May proceed without results if delay endangers patient\n\n### Treatment-Specific Considerations\n\n#### Oxaliplatin\n- Contraindicated if: prior adjuvant treatment within 12 months, preexisting neuropathy >grade 1\n- If \u2265grade 2 neuropathy develops, discontinue oxaliplatin but continue fluoropyrimidine\n- Benefit unclear in patients >70 years\n\n#### Capecitabine\n- Avoid if: adherence issues, inability to self-report toxicity, severe renal impairment (CrCl <30ml/min)\n\n#### Bevacizumab\n- Requirements: ECOG PS 0-2, ANC >1500/mm\u00b3\n- Contraindicated if: non-healing wounds, recent surgery, bleeding disorders, GI perforation history, unstable cardiac conditions, uncontrolled hypertension, or active cocaine use\n\n### Clinical Trials\n- Should always be considered throughout the pathway\n- For assistance: CancerClinicalTrialsNavigation@va.gov\n\n## KEY ABBREVIATIONS\n- CAPOX: Capecitabine + Oxaliplatin\n- CGP: Comprehensive Genomic Profiling\n- dMMR: Mismatch Repair Deficient\n- DPYD: Dihydropyrimidine Dehydrogenase\n- FOLFIRI: Leucovorin, Fluorouracil, Irinotecan\n- mFOLFOX6: Modified FOLFOX6 (Leucovorin, Fluorouracil, Oxaliplatin)\n- MSI-H: Microsatellite Instability High\n- MSS: Microsatellite Stable\n- pMMR: Proficient Mismatch Repair\n\nThis clinical pathway represents version 1-2025 of the colon cancer management guidelines, emphasizing personalized care based on molecular characteristics, disease stage, and patient factors.",
    "thinking": "Based on the page analyses provided, I'll create a comprehensive summary of the clinical pathway for colon cancer. I'll organize it systematically to cover all the key components including staging, assessment, treatment algorithms, and molecular testing.\n\n# COMPREHENSIVE SUMMARY OF COLON CANCER CLINICAL PATHWAY\n\nI'll structure this summary as follows:\n1. Introduction and Overview\n2. Initial Assessment and Staging\n3. Treatment Algorithms by Stage\n   - Stage I Colon Cancer\n   - Stage II Colon Cancer\n   - Stage III Colon Cancer\n   - Stage IV Colon Cancer\n     - Potentially Resectable\n     - Unresectable\n4. Molecular Testing Protocols\n5. Special Considerations\n6. Terminology and Abbreviations\n\nLet's construct the full summary:\n\n## 1. INTRODUCTION AND OVERVIEW\n\nThis clinical pathway provides evidence-based guidance for the diagnosis, evaluation, and management of colon cancer across all stages. The pathway emphasizes personalized treatment approaches based on disease stage, molecular characteristics, and patient-specific factors. Key features include:\n\n- Stage-specific treatment algorithms\n- Integration of molecular testing to guide therapy selection\n- Risk-stratified approaches to adjuvant therapy\n- Sequential treatment strategies for advanced disease\n- Consideration of patient factors in treatment selection\n\nThe pathway incorporates the latest clinical evidence to optimize patient outcomes while considering individualized treatment goals and preferences.\n\n## 2. INITIAL ASSESSMENT AND STAGING\n\n### Initial Diagnostic Workup\n- Complete history and physical examination\n- Colonoscopy with biopsy\n- Pathologic confirmation of adenocarcinoma\n- Staging evaluation including CT chest/abdomen/pelvis\n\n### Staging Classification\n- **Stage I**: T1-2, N0, M0\n- **Stage II**: T3-4, N0, M0\n- **Stage III**: Any T, N1-2, M0\n- **Stage IV**: Any T, Any N, M1\n\n### Presumptive Service Connection for Veterans\nFor VA purposes, colon cancer is presumed to be service-connected in:\n- **Atomic Veterans (Radiation-Exposed)**: Veterans exposed to ionizing radiation during military service\n- **Gulf War and Post 9/11 Veterans**: Those who served on or after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen; or on or after August 2, 1990 in Southwest Asia theater of operations or Somalia\n\n## 3. TREATMENT ALGORITHMS BY STAGE\n\n### STAGE I COLON CANCER\n\n#### Initial Assessment\n- DPYD testing (if fluoropyrimidine therapy anticipated)\n- Determine type of initial resection performed\n\n#### Treatment Pathway\n1. **For Completely Resected Malignant Polyp (Polypectomy):**\n   - Assess for high-risk features:\n     - **Sessile Polyps:** poor differentiation, lymphovascular invasion, submucosal invasion >1mm, tumor at cautery margin, tumor budding\n     - **Pedunculated Polyps:** poor differentiation, lymphovascular invasion, tumor within 1mm of resection margin\n   \n   - **If High Risk Features Present:**\n     \u2192 Proceed to surgical resection\n     \u2192 Follow appropriately staged pathway based on surgical findings\n   \n   - **If No High Risk Features:**\n     - **For Sessile Polyp:**\n       \u2192 Shared decision making between surgical resection or endoscopic surveillance\n     - **For Pedunculated Polyp:**\n       \u2192 Endoscopic surveillance\n\n2. **For Surgically Resected Colon Cancer (Colectomy):**\n   \u2192 Active surveillance (no adjuvant therapy required)\n\n#### Follow-up\n- Regular surveillance according to established guidelines\n\n### STAGE II COLON CANCER\n\n#### Initial Assessment\n- DPYD testing required before fluoropyrimidine therapy\n- MMR status determination by IHC and/or MSI by PCR\n- Risk stratification based on clinicopathologic features\n\n#### Risk Stratification Criteria\nHigh risk features include:\n- Clinical obstruction\n- Localized tumor perforation\n- Poorly differentiated tumor (pMMR only)\n- Lymphovascular invasion\n- Perineural invasion\n- <12 harvested lymph nodes\n- Positive/close margin (\u22641mm in non-peritonelized margins)\n- High tumor budding\n\n#### Treatment Algorithm Based on MMR Status\n\n1. **For dMMR (MSI-H) Patients:**\n   - **High Risk (\u22651 risk factor):**\n     \u2192 Shared decision making between:\n       * CAPOX (3 months) or mFOLFOX6 (3-6 months)\n       * Observation\n   - **Low Risk (no risk factors):**\n     \u2192 Observation recommended\n\n2. **For pMMR (MSS) Patients:**\n   - **T4 tumors:**\n     \u2192 Clinical assessment and shared decision making between:\n       * CAPOX (3 months) or mFOLFOX6 (3-6 months)\n       * Capecitabine or fluorouracil (6 months)\n   - **T3 tumors with \u22652 risk factors:**\n     \u2192 Shared decision making between:\n       * Capecitabine or fluorouracil (6 months)\n       * Observation\n   - **No risk factors:**\n     \u2192 Observation recommended\n\n#### Timing of Therapy\n- Adjuvant chemotherapy should begin 6-8 weeks following surgery\n- Delay beyond 3 months significantly reduces efficacy\n\n### STAGE III COLON CANCER\n\n#### Initial Assessment\n- DPYD testing required\n- MMR status determination\n- Clinical risk assessment based on T and N stage\n\n#### Treatment Algorithm by MMR Status and Risk\n\n1. **For dMMR (MSI-H) Patients:**\n   - **High Risk (T4 and/or N2):**\n     \u2192 Shared decision making between CAPOX (6 months) or mFOLFOX6 (6 months)\n   - **Low Risk (T1-3 and N1):**\n     \u2192 CAPOX (3 months)\n\n2. **For pMMR (MSS) Patients:**\n   - **High Risk (T4 and/or N2):**\n     - **If prohibitive neuropathy present:**\n       \u2192 Capecitabine or fluorouracil (6 months)\n     - **If no prohibitive neuropathy:**\n       \u2192 CAPOX (6 months) or mFOLFOX6 (6 months)\n   - **Low Risk (T1-3 and N1):**\n     \u2192 Shared decision making between:\n       * CAPOX (3 months)\n       * Capecitabine or fluorouracil (6 months)\n\n#### Important Considerations\n- Chemotherapy initiation recommended 6-8 weeks following surgery\n- If \u2265 grade 2 neuropathy develops, discontinue oxaliplatin while continuing fluoropyrimidine\n- Benefit of adding oxaliplatin unclear in patients >70 years old\n- Avoid capecitabine if adherence issues, inability to self-report toxicity, or severe renal impairment (CrCl <30ml/min)\n\n### STAGE IV COLON CANCER\n\n#### Initial Evaluation\n- DPYD testing required if fluoropyrimidine planned\n- Comprehensive molecular testing including:\n  * MMR/MSI status\n  * RAS mutation status\n  * BRAF mutation status\n  * HER2 overexpression\n  * NTRK fusion testing\n  * KRAS G12C mutation testing\n- Multidisciplinary discussion required\n- Assessment of resectability (resectable, potentially resectable, or unresectable)\n- For unresectable disease: assessment of fitness for combination chemotherapy\n\n#### A. POTENTIALLY RESECTABLE DISEASE\n\n1. **For Immediate Resection Candidates:**\n   \u2192 Metastasis and primary directed local therapy\n   \u2192 Assess candidacy for oxaliplatin\n     - **If candidate:** mFOLFOX6 or CAPOX (3 months)\n     - **If not candidate:** Capecitabine or fluorouracil (6 months)\n\n2. **For Non-Immediate Resection Candidates:**\n   \u2192 Assess candidacy for oxaliplatin\n     - **If candidate:** \n       * For aggressive approach: mFOLFIRINOX \u00b1 bevacizumab (up to 4 months)\n       * Otherwise: mFOLFOX6 or CAPOX \u00b1 bevacizumab (up to 4 months)\n     - **If not candidate:** FOLFIRI (up to 4 months)\n   \n   \u2192 Reassess resectability every 2 months\n     - **If becomes resectable:** Proceed to local therapy \u2192 Complete 6 months of chemotherapy\n     - **If remains unresectable:** Continue systemic therapy with reassessment\n\n#### B. UNRESECTABLE DISEASE\n\n##### 1. MMR Status Assessment\n- **If dMMR (MSI-H):**\n  \u2192 First-line therapy: Pembrolizumab\n  \u2192 If progression occurs, assess fitness for combination chemotherapy\n    * **If fit:** Follow pMMR First Line pathway\n    * **If unfit:** Follow unfit for combination chemotherapy pathway\n\n- **If pMMR (MSS):**\n  \u2192 Assess fitness for combination chemotherapy\n\n##### 2. For pMMR (MSS) Fit for Combination Chemotherapy\n\n###### FIRST-LINE THERAPY\nBased on molecular testing and primary tumor location:\n\n- **For RASwt, BRAFwt with left-sided primary:**\n  - **If candidate for oxaliplatin:** mFOLFOX6 or CAPOX + panitumumab\n  - **If not candidate for oxaliplatin:** FOLFIRI + panitumumab\n\n- **For RASmut, BRAFwt with right-sided primary:**\n  - **If candidate for bevacizumab:** mFOLFOX6 or CAPOX + bevacizumab\n  - **If not candidate for bevacizumab:** mFOLFOX6 or CAPOX\n\n- **For RASmut, BRAFwt (side not specified):**\n  - **If candidate for oxaliplatin:**\n    * If candidate for bevacizumab: mFOLFOX6 or CAPOX + bevacizumab\n    * If not candidate for bevacizumab: mFOLFOX6 or CAPOX\n  - **If not candidate for oxaliplatin:**\n    * If candidate for bevacizumab: FOLFIRI + bevacizumab\n    * If not candidate for bevacizumab: FOLFIRI\n\n- **For RASwt, BRAF mutant:**\n  - Treatment depends on specific mutation and prior therapy\n\n###### SECOND-LINE THERAPY\nBased on molecular biomarkers and prior therapy:\n\n- **For actionable mutations:**\n  - **BRAF V600E positive:** Encorafenib + panitumumab\n  - **NTRK fusion positive:** Larotrectinib\n  - **HER2 overexpression (IHC 3+) or ERBB2 amplified AND RASwt AND BRAFwt:** Trastuzumab + pertuzumab\n\n- **For patients without actionable mutations:**\n  - **If prior irinotecan-based regimen:**\n    * **If prior anti-EGFR treatment:**\n      * If candidate for oxaliplatin: mFOLFOX or CAPOX \u00b1 bevacizumab\n      * If not candidate for oxaliplatin: \n        * If KRAS G12C mutation: Adagrasib + cetuximab\n        * If no KRAS G12C mutation: Trifluridine tipiracil \u00b1 bevacizumab\n    * **If no prior anti-EGFR treatment:**\n      * FOLFIRI or irinotecan with panitumumab\n  \n  - **If prior oxaliplatin-based regimen:**\n    * FOLFIRI \u00b1 bevacizumab\n\n###### THIRD-LINE THERAPY\nBased on molecular status and prior therapy:\n\n- **If HER2 overexpression:** Fam-trastuzumab deruxtecan\n\n- **If RAS wild type, BRAF wild type:**\n  - **If prior anti-EGFR treatment:**\n    * If prior trifluridine tipiracil: Fruquintinib\n    * If no prior trifluridine tipiracil: Panitumumab\n  - **If no prior anti-EGFR treatment:**\n    * If candidate for bevacizumab: Trifluridine tipiracil + bevacizumab\n    * If not candidate for bevacizumab: Trifluridine tipiracil\n\n- **If RAS mutant or BRAF mutant:**\n  - **If KRAS G12C mutation:** Adagrasib + cetuximab\n  - **If no KRAS G12C mutation:**\n    * If prior trifluridine tipiracil: Fruquintinib\n    * If no prior trifluridine tipiracil:\n      * If candidate for bevacizumab: Trifluridine tipiracil + bevacizumab\n      * If not candidate for bevacizumab: Trifluridine tipiracil\n\n###### FOURTH-LINE THERAPY\nWith referral to Palliative Care:\n\n- **If KRAS G12C mutation present:** Adagrasib + cetuximab (if no prior use of KRAS G12C inhibitor)\n\n- **If KRAS G12C mutation not present:**\n  - Fruquintinib (if no prior failure)\n  - Trifluridine tipiracil + bevacizumab (if no prior failure and bevacizumab candidate)\n  - mFOLFOX6 or CAPOX (if well tolerated previously, >12 months since last treatment, no \u2265 grade 2 neuropathy)\n  - FOLFIRI (if well tolerated previously, >12 months since last treatment)\n\n##### 3. For pMMR (MSS) Unfit for Combination Chemotherapy\n\n###### FIRST-LINE THERAPY\n- Fluorouracil (5-FU) monotherapy (preferred: infusional)\n- Alternative: Capecitabine (if pump not tolerated, no adherence issues, adequate renal function)\n\n###### UPON PROGRESSION\nBased on molecular status:\n\n- **If RAS wild type and BRAF wild type:**\n  - **If HER2 overexpression:** Trastuzumab + pertuzumab\n  - **If no HER2 overexpression:** Panitumumab\n\n- **If BRAF V600E mutation:** Encorafenib + panitumumab\n\n- **If RAS mutation or BRAF non-V600E:** Irinotecan\n\n- **If KRAS G12C mutation:** Adagrasib + cetuximab\n\n## 4. MOLECULAR TESTING PROTOCOLS\n\n### Testing Indications\n- **Stage I-III:** MMR/MSI testing\n- **Stage IV:** Comprehensive genomic profiling including MMR/MSI, RAS, BRAF, HER2, NTRK, KRAS G12C\n- **Age <50 at diagnosis:** Germline testing regardless of stage\n- **Age \u226550 with relevant personal/family history:** Consider germline testing\n\n### Testing Algorithm by Stage\n\n#### STAGE I-II PATIENTS\n1. **Initial MMR/MSI Testing:**\n   - IHC Testing for MMR protein expression (MLH1, MSH2, MSH6, PMS2), OR\n   - PCR Testing for MSI status\n\n2. **Follow-up Testing:**\n   - **If MLH1/PMS2 loss by IHC or MSI-H:**\n     \u2192 BRAF V600E testing\n     \u2192 If BRAF mutated: Suggests somatic mutation\n     \u2192 If BRAF unmutated: Proceed to methylation testing\n\n3. **Methylation Testing:**\n   - MLH1 promoter hypermethylation testing\n     \u2192 If hypermethylated: Suggests somatic mutation\n     \u2192 If unmethylated: Proceed to Germline Lynch testing\n\n4. **Germline Testing:**\n   - Indicated if:\n     * MSH2 or MSH6 loss by IHC, OR\n     * MLH1/PMS2 loss by IHC + MLH1 unmethylated, OR\n     * MSI-H without IHC + BRAF unmutated + MLH1 unmethylated\n\n#### STAGE IV PATIENTS\n1. **Initial Testing:**\n   - IHC for MMR protein expression\n   - Comprehensive genomic profiling (CGP) including:\n     * MSI status\n     * RAS mutation analysis\n     * BRAF mutation analysis\n     * HER2/ERBB2 testing\n     * NTRK fusion analysis\n     * KRAS G12C mutation testing\n\n2. **If dMMR (MSI-H) detected:**\n   - Perform Lynch testing if germline testing not previously performed\n\n### Germline Testing\n1. **Full Germline Panel Components:**\n   - Minimum gene panel: APC, AXIN2, BMPR1A, CHEK2, EPCAM, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, SMAD4, STK11, and TP53\n\n2. **Lynch Testing Components:**\n   - Minimum panel: EPCAM, MLH1, MSH2, MSH6, and PMS2\n\n3. **Personal/Family History Indicators:**\n   - Multiple polyps\n   - Lynch syndrome or other hereditary cancer syndromes\n   - Associated cancers (colorectal, endometrial, gastric, ovarian, pancreas, urethral, brain tumors)\n   - Sebaceous adenomas/carcinomas and keratoacanthomas (Muir-Torre syndrome)\n   - Known pathogenic/likely pathogenic variant in family\n\n## 5. SPECIAL CONSIDERATIONS\n\n### DPYD Testing\n- Required before fluoropyrimidine therapy\n- If results show intermediate/poor metabolizer status, consult pharmacist\n- May proceed without results if withholding therapy for 2-3 weeks would endanger patient\n\n### Oxaliplatin Eligibility\n- Contraindicated if:\n  * Adjuvant treatment in past 12 months\n  * Preexisting neuropathy >grade 1\n  * Patient preference to avoid neuropathy\n- If \u2265grade 2 neuropathy develops, discontinue oxaliplatin while continuing fluoropyrimidine\n- Benefit unclear in patients >70 years old\n\n### Capecitabine Considerations\n- Avoid if:\n  * Adherence issues\n  * Inability to self-report toxicity\n  * Severe renal impairment (CrCl <30ml/min)\n\n### Bevacizumab Eligibility\n- Requirements: ECOG PS 0-2, ANC >1500/mm\u00b3\n- Contraindicated if:\n  * Non-healing wound/fracture\n  * Major surgery in prior 4 weeks\n  * Bleeding disorder or coagulopathy\n  * Recent GI perforation\n  * Unstable cardiac condition\n  * Uncontrolled hypertension\n  * Arterial thromboembolism\n  * Symptomatic CHF\n  * Active cocaine use\n\n### Clinical Trials\n- Clinical trials should always be considered throughout the pathway\n- For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov\n\n## 6. TERMINOLOGY AND ABBREVIATIONS\n\n- **ANC**: Absolute Neutrophil Count\n- **CAPOX**: Capecitabine plus Oxaliplatin\n- **CGP**: Comprehensive Genomic Profiling\n- **CrCl**: Creatinine Clearance\n- **dMMR**: Mismatch Repair Deficient\n- **DPYD**: Dihydropyrimidine Dehydrogenase\n- **EGFR**: Epidermal Growth Factor Receptor\n- **FOLFIRI**: Leucovorin, Fluorouracil, and Irinotecan\n- **mFOLFOX6**: Modified FOLFOX6 (Leucovorin, Fluorouracil, and Oxaliplatin)\n- **mFOLFIRINOX**: Modified FOLFIRINOX (Leucovorin, Fluorouracil, Irinotecan, and Oxaliplatin)\n- **MMR**: Mismatch Repair\n- **MSI**: Microsatellite Instability\n- **MSI-H**: Microsatellite Instability High\n- **MSS**: Microsatellite Stable\n- **mut**: Mutation\n- **PCR**: Polymerase Chain Reaction\n- **pMMR**: Proficient Mismatch Repair\n- **wt**: Wild Type"
  }
}